What is the role of medical societies in developing guidelines for eculizumab use?

Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ... The generic drug name is eculizumab (ek-u-liz-oo-mab). Soliris® is a brand ... Eculizumab is a monoclonal antibody, a type of targeted therapy. It. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Soliris ... 600mg weekly for the first 4 weeks, followed by 900mg for the fifth dose 1 week later, then 900mg every 2 weeks thereafter. Mar 6, 2012 ... For these very small children, eculizumab should be considered first. In larger children who can be treated with plasma exchange, treatment with ... Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week, followed by maintenance 1.2 g every 12–16 days, consider ... About This Drug. Eculizumab-xxxx (Soliris, Bkemv) is used to treat some blood disorders and nerve disorders. It is given in the vein (IV). View the fact sheet ... Mar 10, 2025 ... FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children ... This landmark ... Jul 14, 2017 ... What is already known about this topic? Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a ...